On the contrary, it remains questionable whether immunotherapy has a therapeutic role in NSCLC with mutations in SMARCA4. A small number of studies in the literature have shown promising results regarding the use of immunotherapy. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.